Content area
Abstract
Clinical studies of the effect of probiotics on plasma TMAO levels and on cardiovascular disease in humans would be of interest. Because TMAO is produced in the liver by the action of the flavin monooxygenase FMO3, inhibition of this enzyme in the liver might be another strategy by which to reduce TMAO production and cut the risk of heart disease.